Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers

In digestive oncology, the clinical impact of targeted next-generation sequencing (NGS) in routine practice should be addressed. In this work, we studied the impact of a 22-gene NGS amplicon-based panel with Ion Torrent Proton Sequencing, prospectively performed in routine practice. We analyzed the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arnaud Bayle, Debora Basile, Simon Garinet, Bastien Rance, Pierre Laurent-Puig, Hélène Blons, Julien Taieb, Geraldine Perkins
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	next-generation sequencing digestive cancer colon cancer oncology genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0b7ea37bfe5747a9b46149a9c8fd4522
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0b7ea37bfe5747a9b46149a9c8fd4522
record_format	dspace
spelling	oai:doaj.org-article:0b7ea37bfe5747a9b46149a9c8fd45222021-11-25T17:03:34ZNext-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers10.3390/cancers132257502072-6694https://doaj.org/article/0b7ea37bfe5747a9b46149a9c8fd45222021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5750https://doaj.org/toc/2072-6694In digestive oncology, the clinical impact of targeted next-generation sequencing (NGS) in routine practice should be addressed. In this work, we studied the impact of a 22-gene NGS amplicon-based panel with Ion Torrent Proton Sequencing, prospectively performed in routine practice. We analyzed the results of extended molecular testing, beyond <i>RAS</i> and <i>BRAF,</i> in metastatic colorectal cancer (mCRC) patients in a single-center, retrospective, observational study of consecutive mCRC patients followed up at the Georges Pompidou European Hospital between January 2016 and December 2018. Overall, 210 patients with mCRC were included. Median follow-up was 25.4 months (IQR: 14.9–39.5). The three most frequently mutated genes were: <i>TP53</i> (63%), <i>KRAS</i> (41%) and <i>PIK3CA</i> (19%). A positive association was found between overall survival and performance status (PS) ≥ 2 (HR: 4.91 (1.84–13.1); <i>p</i> = 0.001) and differentiation (HR: 4.70 (1.51–14.6); <i>p</i> = 0.007) in multivariate analysis. The NGS panel enabled five patients to access a targeted therapy not currently registered for CRC. In conclusion, targeted NGS panels in mCRC are feasible in routine practice, but need to be regularly updated and in-depth studies are needed to better analyze the prognostic factors.Arnaud BayleDebora BasileSimon GarinetBastien RancePierre Laurent-PuigHélène BlonsJulien TaiebGeraldine PerkinsMDPI AGarticlenext-generation sequencingdigestive cancercolon canceroncologygenomicsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5750, p 5750 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	next-generation sequencing digestive cancer colon cancer oncology genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	next-generation sequencing digestive cancer colon cancer oncology genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Arnaud Bayle Debora Basile Simon Garinet Bastien Rance Pierre Laurent-Puig Hélène Blons Julien Taieb Geraldine Perkins Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
description	In digestive oncology, the clinical impact of targeted next-generation sequencing (NGS) in routine practice should be addressed. In this work, we studied the impact of a 22-gene NGS amplicon-based panel with Ion Torrent Proton Sequencing, prospectively performed in routine practice. We analyzed the results of extended molecular testing, beyond <i>RAS</i> and <i>BRAF,</i> in metastatic colorectal cancer (mCRC) patients in a single-center, retrospective, observational study of consecutive mCRC patients followed up at the Georges Pompidou European Hospital between January 2016 and December 2018. Overall, 210 patients with mCRC were included. Median follow-up was 25.4 months (IQR: 14.9–39.5). The three most frequently mutated genes were: <i>TP53</i> (63%), <i>KRAS</i> (41%) and <i>PIK3CA</i> (19%). A positive association was found between overall survival and performance status (PS) ≥ 2 (HR: 4.91 (1.84–13.1); <i>p</i> = 0.001) and differentiation (HR: 4.70 (1.51–14.6); <i>p</i> = 0.007) in multivariate analysis. The NGS panel enabled five patients to access a targeted therapy not currently registered for CRC. In conclusion, targeted NGS panels in mCRC are feasible in routine practice, but need to be regularly updated and in-depth studies are needed to better analyze the prognostic factors.
format	article
author	Arnaud Bayle Debora Basile Simon Garinet Bastien Rance Pierre Laurent-Puig Hélène Blons Julien Taieb Geraldine Perkins
author_facet	Arnaud Bayle Debora Basile Simon Garinet Bastien Rance Pierre Laurent-Puig Hélène Blons Julien Taieb Geraldine Perkins
author_sort	Arnaud Bayle
title	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
title_short	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
title_full	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
title_fullStr	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
title_full_unstemmed	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
title_sort	next-generation sequencing targeted panel in routine care for metastatic colon cancers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0b7ea37bfe5747a9b46149a9c8fd4522
work_keys_str_mv	AT arnaudbayle nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT deborabasile nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT simongarinet nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT bastienrance nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT pierrelaurentpuig nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT heleneblons nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT julientaieb nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers AT geraldineperkins nextgenerationsequencingtargetedpanelinroutinecareformetastaticcoloncancers
_version_	1718412756362723328

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers

Ejemplares similares